Mattis Ralf Otfried Bertlich

Prof. Dr. Mattis Ralf Otfried Bertlich


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FIFritz Ihler
Fritz Ihler
MBMattis Ralf Otfried Bertlich
Mattis Ralf Otfried Bertlich
KSKariem Sharaf
Kariem Sharaf
SSSebastian Strieth
Sebastian Strieth
MSMichael Strupp
Michael Strupp
MCMartin Canis
Martin Canis
Betahistine is a histamine H1-receptor agonist and H3-receptor antagonist that is administered to treat Menière’s disease. Despite widespread use, its pharmacological mode of action has not been entirely elucidated. This study investigated the effect of betahistine on guinea pigs at dosages corresponding to clinically used doses for cochlear microcirculation. Thirty healthy Dunkin-Hartley guinea pigs were randomly assigned to five groups to receive betahistine dihydrochloride in a dose of 1,000 mg/kg b. w. (milligram per kilogram body weight), 0.100 mg/kg b. w., 0.010 mg/kg b. w., 0.001 mg/kg b. w. in NaCl 0.9% or NaCl 0.9% alone as placebo. Cochlear blood flow and mean arterial pressure were continuously monitored by intravital fluorescence microscopy and invasive blood pressure measurements 3 minutes before and 15 minutes after administration of betahistine. When betahistine was administered in a dose of 1.000 mg/kg b. w. cochlear blood flow was increased to a peak value of 1.340 arbitrary units (SD: 0.246; range: 0.933–1.546 arb. units) compared to baseline (p<0.05; Two Way Repeated Measures ANOVA/Bonferroni t-test). The lowest dosage of 0.001 mg/kg b. w. betahistine or NaCl 0.9% had the same effect as placebo. Nonlinear regression revealed that there was a sigmoid correlation between increase in blood flow and dosages. Betahistine has a dose-dependent effect on the increase of blood flow in cochlear capillaries. The effects of the dosage range of betahistine on cochlear microcirculation corresponded well to clinically used single dosages to treat Menière’s disease. Our data suggest that the improved effects of higher doses of betahistine in the treatment of Menière’s disease might be due to a corresponding increase of cochlear blood flow.

27 June 2015 in Audiology and Neurotology
Verified
Journal Article
Closed access
MBMattis Ralf Otfried Bertlich
Mattis Ralf Otfried Bertlich
FIFriedrich Ihler
Friedrich Ihler
SFSaskia Freytag
Saskia Freytag
BWBernhard G. Weiss
Bernhard G. Weiss
MSMichael Strupp
Michael Strupp
MCMartin Canis
Martin Canis
Objective: Betahistine is a histamine-like drug that is considered beneficial in Ménière's disease by increasing cochlear blood flow. Acting as an agonist at the histamine H1-receptor and as an inverse agonist at the H3-receptor, these receptors as well as the adrenergic α2-receptor were investigated for betahistine effects on cochlear blood flow. Materials and Methods: A total of 54 Dunkin-Hartley guinea pigs were randomly assigned to one of nine groups treated with a selection of H1-, H3- or α2-selective agonists and antagonists together with betahistine. Cochlear blood flow and mean arterial pressure were recorded for 3 min before and 15 min after infusion. Results: Blockage of the H3- or α2-receptors caused a suppression of betahistine-mediated typical changes in cochlear blood flow or blood pressure. Activation of H3-receptors caused a drop in cochlear blood flow and blood pressure. H1-receptors showed no involvement in betahistine-mediated changes of cochlear blood flow. Conclusion: Betahistine most likely affects cochlear blood flow through histaminergic H3-heteroreceptors.

30 June 2014 in International Journal of Audiology
Verified
Journal Article
Closed access
MBMattis Ralf Otfried Bertlich
Mattis Ralf Otfried Bertlich
FIFritz Ihler
Fritz Ihler
KSKariem Sharaf
Kariem Sharaf
BWBernhard G. Weiss
Bernhard G. Weiss
MSMichael Strupp
Michael Strupp
MCMartin Canis
Martin Canis
Betahistine is a histamine-like drug that is used in the treatment of Ménière's disease. It is commonly believed that betahistine increases cochlear blood flow and thus decreases the endolymphatic hydrops that is the cause of Ménière's. Despite common clinical use, there is little understanding of the kinetics or effects of its metabolites. This study investigated the effect of the betahistine metabolites aminoethylpyridine, hydroxyethylpyridine, and pyridylacetic acid on cochlear microcirculation. Guinea pigs were randomly assigned to one of the groups: placebo, betahistine, or equimolar amounts of aminoethylpyridine, hydroxyethylpyridine, or pyridylacetic acid. Cochlear blood flow and mean arterial pressure were recorded for three minutes before and 15 minutes after treatment. Thirty Dunkin-Hartley guinea pigs assigned to one of five groups with six guinea pigs per group. Betahistine, aminoethylpyridine, and hydroxyethylpyridine caused a significant increase in cochlear blood flow in comparison to placebo. The effect seen under aminoethylpyridin was greatest. The group treated with pyridylacetic acid showed no significant effect on cochlear blood flow. Aminoethylpyridine and hydroxyethylpyridine are, like betahistine, able to increase cochlear blood flow significantly. The effect of aminoethylpyridine was greatest. Pyridylacetic acid had no effect on cochlear microcirculation.

2 March 2017 in Head & Neck
Verified
Journal Article
Closed access
PDF file
BWBernhard G. Weiss
Bernhard G. Weiss
MBMattis Ralf Otfried Bertlich
Mattis Ralf Otfried Bertlich
MCMartin Canis
Martin Canis
FIFriedrich Ihler
Friedrich Ihler

2 April 2019
Verified
Book Chapter
Closed access
PDF file
MCMartin Canis
Martin Canis
MBMattis Ralf Otfried Bertlich
Mattis Ralf Otfried Bertlich

1 July 2013 in Annals of Otology, Rhinology & Laryngology
Verified
Journal Article
Closed access
PDF file
FIFriedrich Ihler
Friedrich Ihler
KSKariem Sharaf
Kariem Sharaf
MBMattis Ralf Otfried Bertlich
Mattis Ralf Otfried Bertlich
SSSebastian Strieth
Sebastian Strieth
CRChristoph A. Reichel
Christoph A. Reichel
MCMartin Canis
Martin Canis
Objectives: Tumor necrosis factor alpha (TNF-alpha) is a mediator of inflammation and microcirculation in the cochlea. This study aimed to quantify the effect of a local increase of TNF-alpha and study the effect of its interaction with etanercept on cochlear microcirculation. Methods: Cochlear lateral wall vessels were exposed surgically and assessed by intravital microscopy in guinea pigs in vivo. First, 24 animals were randomly distributed into 4 groups of 6 each. Exposed vessels were superfused repeatedly either with 1 of 3 different concentrations of TNF-alpha (5.0, 0.5, and 0.05 ng/mL) or with placebo (0.9% saline solution). Second, 12 animals were randomly distributed into 2 groups of 6 each. Vessels were pretreated with etanercept (1.0 μg/mL) or placebo (0.9% saline solution), and then treated by repeated superfusion with TNF-alpha (5.0 ng/mL). Results: TNF-alpha was shown to be effective in decreasing cochlear blood flow at a dose of 5.0 ng/mL (p < 0.01, analysis of variance on ranks). Lower concentrations or placebo treatment did not lead to significant changes. After pretreatment with etanercept, TNF-alpha at a dose of 5.0 ng/mL no longer led to a change in cochlear blood flow. Conclusions: The decreasing effect that TNF-alpha has on cochlear blood flow is dose-dependent. Etanercept abrogates this effect.